Literature DB >> 12614732

Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients.

Nina Singh1.   

Abstract

The spectrum of infections in transplant recipients has been substantially affected by novel immunosuppressive regimens and the use of antimicrobial agents. Epidemiology and presentation of traditional opportunistic pathogens has changed. Invasive aspergillosis and cytomegalovirus occur later in the post-transplant period. The incidence of infections that were previously encountered rarely--eg, BK virus nephropathy--has increased, the clinical course of hepatitis C virus recurrence has become more aggressive, the risk factors for invasive aspergillosis have changed, and non-aspergillus moulds are occurring more commonly in transplant recipients. Recognition of these trends as they unfold has significant implications for the clinical care of the transplant recipients, for providing insights into the pathogenesis, and for continually improving the approaches to the management of infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614732     DOI: 10.1016/s1473-3099(03)00546-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  11 in total

1.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.

Authors:  Koichi Araki; Shivaprakash Gangappa; Dirck L Dillehay; Barry T Rouse; Christian P Larsen; Rafi Ahmed
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

3.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.

Authors:  Carol Garcia-Vidal; Arlo Upton; Katharine A Kirby; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

4.  Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.

Authors:  Gregory A Lamaris; Russell E Lewis; Georgios Chamilos; Gregory S May; Amar Safdar; Thomas J Walsh; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

Review 5.  Patients at high risk of invasive fungal infections: when and how to treat.

Authors:  Maria J G T Rüping; Jörg J Vehreschild; Oliver A Cornely
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  CNS aspergillosis: recognition, diagnosis and management.

Authors:  Markus Ruhnke; Grzegorz Kofla; Kirsten Otto; Stefan Schwartz
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.

Authors:  Georg Maschmeyer; Antje Haas; Oliver A Cornely
Journal:  Drugs       Date:  2007       Impact factor: 11.431

8.  Update on the treatment of disseminated fusariosis: Focus on voriconazole.

Authors:  Marta Stanzani; Fabio Tumietto; Nicola Vianelli; Michele Baccarani
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

9.  Structural requirements for the antifungal activities of natural drimane sesquiterpenes and analogues, supported by conformational and electronic studies.

Authors:  Marcos Derita; Iván Montenegro; Francisco Garibotto; Ricardo D Enriz; Mauricio Cuellar Fritis; Susana A Zacchino
Journal:  Molecules       Date:  2013-02-05       Impact factor: 4.411

10.  Antifungal activity of Thymus vulgaris L. essential oil and its constituent phytochemicals against Rhizopus oryzae: interaction with ergosterol.

Authors:  Kelly Samara de Lira Mota; Fillipe de Oliveira Pereira; Wylly Araújo de Oliveira; Igara Oliveira Lima; Edeltrudes de Oliveira Lima
Journal:  Molecules       Date:  2012-12-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.